Myozyme User Fee Goal Extended Until April
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme says the extension for the Pompe disease treatment is intended to provide the FDA time to review clarifying information.
You may also be interested in...
Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Genzyme’s Pompe disease orphan biologic was approved April 28.
Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Genzyme’s Pompe disease orphan biologic was approved April 28.
Genzyme Myozyme BLA For Pompe Disease Could Clear FDA By January
Genzyme expects its BLA for Myozyme (alglucosidase alfa) will receive a priority review from FDA for treatment of Pompe disease, the firm said July 29